Equity Overview
Price & Market Data
Price: $0.86
Daily Change: +$0.0399 / 4.64%
Range: $0.80 - $0.86
Market Cap: $7,881,406
Volume: 111,815
Performance Metrics
1 Week: -15.80%
1 Month: -45.68%
3 Months: -73.27%
6 Months: -91.39%
1 Year: -95.54%
YTD: -78.95%
Company Details
Employees: 23
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.